report earn tuesday apr dial
despit revenu biotech name
rel insensit number outsid
wildcard event number total cf
revenu consensu vs
sequenti declin
telegraph call cite
inventori build last quarter higher vs
quarter note begin record
tax provis year nol
balanc book moder
tax impact potenti sensit bodi
england franc access orkambi
select announc top-lin
fy guidanc recal guid
cf revenu yoy dont
anticip chang cf guidanc time
doubl market cap x-factor focu
recent initi mid-to-larg cap transit
biotech compani leverag infrastructur
launch product acceler growth
wait announc result
dose-rang studi gate factor
progress
pain program studi
complet late januari guid data
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
recent initi line rate within coverag
expans roadmap futur sector modal
compani report earn tuesday apr dial
fundament posit scienc manag believ
street out-year cf franchis estim high due eu price assumpt stock
trade premium base high consensu out-year sale estim vs peer
vs ev/sal thesi deserv higher-than-averag multipl
lower lt number ww revenu number come consensu sole
due eu cf revenu estim consensu assumpt around
underli volum growth drive revenu continu grow elig
patient pool patient label expans across exist product
world-wide symdeko launch continu provid momentum key driver age
expans year vrtx cf revenu guidanc yoy management note
call guidanc base current cf reimburs geographi -- addit
reimburs agreement would repres upsid compani estim dont
anticip near-term us price pressur cf portfolio note state medicaid
payor push back link
consensu vs evr isi estim
bunionectomi dose-rang data path forward pain indic
select vs tripl combin us file mid-year
scottish medicin consortium smc decis orkambi/symdeko
on-going reimburs discuss cf portfolio ex-u time unclear
antitrypsin defici update/data candid enter clinic
increment data gene edit studi
thalassemia announc patient dose sickl cell diseas program
transfusion-depend beta
detail fsg program enter clinic
updat cf studi
view vrtx cf drug accord cumul bucket cf patient gener
new correctors/potenti address cumul patient pool tripl add hetmin
continu label expans across geographi kalydeco
grew yoy vs consensu expect pace
continu forecast flat vs
individu product perform relev instead
focu sum symdeko like exceed orkambi
new start orkambi discontinu orkambi
switch symdeko offer better toler profil expand
mutat coverag rel orkambi
await select vs compon tripl
data top-lin march guid mid-year us file
tripl
keep tab life-cycle manag activ once-
daili deuter ivacaftor studi post clinicaltri gov
gen cf corrector advanc link studi arm includ
age
ev/sales-bas valuat premium vs revenue-gener biotech peer group
ex-u reimburs cystic fibrosi product price pressur market product pipelin risk
articl articl
time dissemin april
analyst josh schimmer shenston huang ravi mehrotra regina grebla maneka mirchandaney primarili respons
prepar research report attest follow view opinion render research report reflect
person view subject compani issuer part research analyst compens directli
relat specif recommend view research report
